Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New combo therapy shows promise for rare lung cancer

NCT ID NCT03762018

Disease control Sponsor: ETOP IBCSG Partners Foundation Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jul 23, 2026 · Updated 2 times

Summary

This study tested whether adding the immunotherapy drug atezolizumab to standard treatment (bevacizumab plus chemotherapy) helps people with advanced malignant pleural mesothelioma live longer. The trial involved 400 adults whose cancer could not be removed by surgery. Researchers measured overall survival and how long the cancer stayed under control.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 3

Large-scale testing in a bigger group. Usually the last step before a treatment can be approved.

Participants

400 people

The number who actually took part.

Started

Apr 2019

Finished

Nov 2024

Lead sponsor

A research network

The lead sponsor is a research network or cooperative group.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Histologically confirmed advanced malignant pleural mesothelioma (all histological subtypes are eligible) * Not amenable for radical surgery based on local standards * Evaluable disease or measurable disease as assessed according to the modified response evaluation criteria for solid tumours for mesothelioma (mRECIST) v1.1 * Availability of tumour tissue for translational research * Age \>18 years * Performance Status 0-1 * Life expectancy \>3 months * Adequate haematological, renal and liver function * Completed baseline quality of life (QoL) questionnaire * Women of childbearing potential and sexually active men must agree to use highly effective contraception * Able to understand and give written informed consent and comply with trial procedures Exclusion Criteria: * Prior treatment for malignant pleural mesothelioma. Prior radiotherapy for symptom control is allowed, but the irradiated lesion cannot be used as target lesion. If the patient has another target lesion, the patient is eligible. * Treatment with systemic immune-stimulatory agents within 4 weeks or five half-lives of the drug prior to randomisation and during protocol treatment. * Treatment with systemic immunosuppressive medications within 2 weeks prior to randomisation and during protocol treatment. * Previous allogeneic tissue/solid organ transplant * Live vaccines within 4 weeks prior to first dose of protocol treatment * Inadequately controlled hypertension * Prior history of hypertensive crisis or hypertensive encephalopathy * Significant vascular disease within 6 months prior to randomisation * History of haemoptysis * Evidence of bleeding diathesis or coagulopathy * Active autoimmune disease that has required systemic treatment in past 2 years * History of active diverticulitis * Previous treatment with atezolizumab and/or bevacizumab or parallel participation in other interventional clinical trial with atezolizumab and/or bevacizumab.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Pleural mesothelioma malignant advanced are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

malignant pleural mesothelioma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Pleural mesothelioma malignant advanced

Contacts and locations

Locations

  • AULSS2 Marca Trevigiana Treviso

    Treviso, Italy

  • Addenbrooke's Hospital

    Cambridge, United Kingdom

  • Alicante University Hospital ISABIAL

    Alicante, Spain

  • CHU Liege

    Liège, Belgium

  • CHUV

    Lausanne, Switzerland

  • Caen- CHU

    Caen, France

  • Clatterbridge Cancer Centre

    Liverpool, United Kingdom

  • Complexo Hospitalario Universitario de Vigo

    Vigo, Spain

  • Curie Cancer Center Paris

    Paris, France

  • Ferdinando Cerciello

    Bern, Switzerland

  • Fondazione IRCCS Istituto Nazionale die Tumori

    Milan, Italy

  • Guy's and St Thomas' Hospital

    London, United Kingdom

  • Hospital Nord

    Marseille, France

  • Hospital Parc Tauli Sabadell

    Sabadell, Spain

  • ICO Hospitalet

    Barcelona, Spain

  • IRCCS Instituto Tumori Giovanni Paolo II

    Bari, Italy

  • Instituto Europeo di Oncologia (IEO)

    Milan, Italy

  • Istituto Oncologica della Svizzera Italiana

    Bellinzona, Switzerland

  • Kantonsspital Aarau

    Aarau, Switzerland

  • Kantonsspital Graubünden

    Chur, Switzerland

  • Kantonsspital St. Gallen

    Sankt Gallen, Switzerland

  • Kantonsspital Winterthur

    Winterthur, Switzerland

  • Kent Oncology Centre

    Maidstone, United Kingdom

  • Le Mans - CHG

    Le Mans, France

  • Luzerner Kantonsspital

    Lucerne, Switzerland

  • Lyon - Centre Léon Bérard

    Lyon, France

  • Plymouth Hospitals NHS Trust

    Plymouth, United Kingdom

  • Puerta de Hierro Hospital

    Majadahonda, Spain

  • Royal Cornwall Hospital

    Truro, United Kingdom

  • Royal Marsden Hospital (Fulham Road)

    London, United Kingdom

  • Royal Marsden Hospital (Sutton)

    London, United Kingdom

  • SS Antonio e Biagio e Cesare Arrigo Hospital

    Alessandria, Italy

  • Toulouse - CHU

    Toulouse, France

  • Tours - CHU

    Tours, France

  • Unicancer - Institut Bergonie

    Bordeaux, France

  • University Hospital Leuven

    Leuven, Belgium

  • University Hospital of Turin

    Turin, Italy

  • UniversitätSpital Zürich

    Zurich, Switzerland

  • Vall Hebron University Hospital/Vall Hebron Institue Oncology

    Barcelona, Spain

  • Virgen del Rocio

    Seville, Spain

  • Weston Park Hospital

    Sheffield, United Kingdom

  • Wythenshawe Hospital

    Manchester, United Kingdom

More trials for these conditions

Other studies related to the condition(s) this trial covers.